Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

Clinical trial NCT02954991 · TERMINATED

Trial details

NCT number: NCT02954991
Sponsor: Mirati Therapeutics Inc.
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Carcinoma, Non-Small-Cell Lung

Start date: 2016-11-07
Primary completion: 2021-11-04
Enrollment: 161

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.